Business Context and Reporting Period
Company: CalciMedica, Inc. (CALC)
Filing Type: Form 8-K (Current Report)
Date: January 28, 2026
Context: The filing discloses the discontinuation of the Phase 2 KOURAGE clinical trial evaluating the company's product candidate, Auxora, for patients with Stage 2 or Stage 3 acute kidney injury (AKI) associated with acute hypoxemic respiratory failure (AHRF).
Key Financial Metrics
This Form 8-K is a current report regarding a specific corporate event and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Events
- Trial Discontinuation: The Independent Data Monitoring Committee (IDMC) recommended stopping the KOURAGE trial following a prescheduled interim data review.
- Safety Concerns: The IDMC identified a safety concern warranting a reevaluation of the study design, specifically regarding patient enrollment criteria.
- Adverse Events: There were no deaths assessed as related to the study drug (Auxora or placebo). No serious adverse events met criteria for expedited reporting to the FDA.
- Regulatory Notification: The Company has notified the FDA of the discontinuation.
Outlook, Management Commentary, and Risks
- Next Steps: The Company plans a comprehensive review of unblinded clinical data to assess the impact of baseline characteristics, disease severity, and concomitant therapies on patient outcomes.
- Future Strategy: These analyses are expected to inform how future clinical evaluation of Auxora in AKI may proceed.
- Patient Follow-up: The Company will work with investigators to ensure all currently enrolled patients complete the full 90-day follow-up.
- Risks: Forward-looking statements are subject to risks including the ability to obtain regulatory approval, potential safety complications, and the need for additional capital. Actual outcomes may differ materially from expectations.
Investor Verification Checklist
- Verify the specific nature of the safety concern identified by the IDMC in the attached press release (Exhibit 99.1).
- Monitor upcoming announcements regarding the results of the comprehensive unblinded data review.
- Assess the impact of the trial discontinuation on the Company's cash runway and potential need for additional capital.
- Review the Company's most recent Form 10-Q (filed November 12, 2025) for detailed financial position and risk factors.